Clinical trials: Normal Drug Tolerance
Impaired Glucose Tolerance
Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)
Lipotoxicity-causing fatty acid overexposure and accretion in lean tissues leads to insulin resistance and impaired pancreatic β-cell function - the hallmarks of T2D - contributing to associated complications such as heart…
- Trial name
- AGL11 (NCT02808182)
- Testing
- Nicotinic acid, [7,7,8,8-2H]-palmitate, [U-13C]-palmitate
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Breast Cancer, Lung Cancer (Non-Small Cell)
Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer
This clinical study evaluates whether a supervised, multimodal therapeutic exercise program started before chemotherapy and continued during treatment can improve treatment outcomes in patients aged 35 to 65 years with breast…
- Conditions
- Breast Cancer, Lung Cancer (Non-Small Cell), Colorectal Cancer, Physical Activity
- Trial name
- PREDU (NCT07502963)
- Testing
- PREDU Exercise Program, Recommendation Exercise Program
- Where
- 3 sites in Spain
- Volunteers
- 70 people
- Sponsor
- University of Vic - Central University of Catalonia
Glioblastoma
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme…
- Trial name
- NCT05664243
- Testing
- Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified gamma-delta T cells
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- In8bio Inc.
Arthritis, Rheumatoid, Synovitis
Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy
The safety profile and efficacy of combination therapy will be evaluated using methotrexate (MTX) and the nucleoside analog fludarabine in 40 patients with severe refractory rheumatoid arthritis.
- Trial name
- NCT00001677
- Testing
- Methotrexate, Fludarabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recessive Dystrophic Epidermolysis Bullosa
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Recessive Dystrophic Epidermolysis Bullosa (RDEB) is one of the most severe rare inherited skin disorders affecting children and adults.
- Trial name
- RDEB (NCT01874769)
- Testing
- Blood collection, Skin biopsies
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Acne Vulgaris
A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris
The study will look to evaluate the tolerance of a light therapy-based acne mask device in participants who report having sensitive skin.
- Trial name
- NCT03128723
- Testing
- Acne Mask
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Melanoma, Urological Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced melanoma or urological cancers who have failed in routine systemic treatment.
- Trial name
- NCT02836795
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Breast Cancer, Ovarian Cancer
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT06738966
- Testing
- BL0175
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04452214
- Testing
- CAN04, Pembrolizumab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cantargia AB
Rosacea, Redness
Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea
Multicentric and double-blind randomised comparative clinical study in Argentina and Brazil. Under dermatological and ophthalmological control 4 visits: inclusion [Day(D)0], D28, D56, D84 Ethical committee required.
- Conditions
- Rosacea, Redness, Telangiectasia, Flushing
- Trial name
- NCT06582043
- Testing
- SCARCr tester 1
- Where
- 2 sites in Argentina, Brazil
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- NAOS Argentina S.A.
Juvenile Idiopathic Arthritis, ALL
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia
Methotrexate is a cornerstone in the treatment of childhood leukemia. When given in high-dose as part of the initial phase of treatment, gastrointestinal toxicity is a known problem.
- Trial name
- NCT02528435
- Volunteers
- 145 people
- Sponsor
- University of Aarhus
Healthy, Melasma (Facial Melasma)
COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS
The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with…
- Conditions
- Healthy, Melasma (Facial Melasma), Epidermal Melasma
- Trial name
- NCT07071363
- Testing
- Depigmenting Cosmetic Serum (Applied Morning and Evening)
- Where
- Mauritius
- Volunteers
- 40 people
- Sponsor
- Laboratoire Dermatologique ACM
Mucopolysaccharidosis Type II, Metabolic Diseases
A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers
It is a phase I open-label single-dose, dose-escalation cohort study to evaluate of the tolerance, safety, and pharmacokinetics of GNR-055 in healthy volunteers
- Trial name
- NCT06475404
- Testing
- verenafusp alfa 6 mg/kg, verenafusp alfa 9 mg/kg, verenafusp alfa 12 mg/kg
- Where
- Russia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AO GENERIUM
Rheumatoid Arthritis
TOLERA: Tolerance Enhancement in RA
Although anti-citrullinated protein antibodies (ACPA) including anti-CCP2 antibodies are known to promote inflammation and joint destruction in patients suffering from ACPA-positive rheumatoid arthritis, there are currently no…
- Trial name
- TOLERA (NCT04120831)
- Testing
- Abatacept Injection
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Cystic Fibrosis, Pancreatic Insufficiency
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop.
- Trial name
- NCT01851694
- Testing
- GLP-1, GIP
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Metastatic Melanoma
Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old
Since 2013, therapeutic care of metastatic melanoma (MM) has greatly improved, especially thanks to BRAF and MEK targeted therapies.
- Trial name
- TOLBRIPA (NCT03155217)
- Where
- France
- Volunteers
- 358 people
- Sponsor
- University Hospital, Montpellier
Obstructive Sleep Apnea, Sleep Apnea
Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism
Obstructive sleep apnea affects approximately 2-4% of middle-aged adults in the general population and is associated with several medical conditions including hypertension and coronary artery.
- Conditions
- Obstructive Sleep Apnea, Sleep Apnea, Sleep-disordered Breathing
- Trial name
- SOMNOS (NCT01503164)
- Testing
- Positive Pressure Therapy (PAP), LifeStyle Counseling
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Johns Hopkins University
Advanced Unresectable or Metastatic Breast Cancer
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults.
- Trial name
- NCT06679036
- Testing
- HRS-2189, Fluvustat, HRS-8080
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Androgenic Alopecia
Assessment of the Effects and Tolerance of the RV4986A Lotion in Men With AGA After Hair Transplant
Alopecia involves a diminution of visible hair that can have significant psychosocial effects and impairment of quality of life.
- Trial name
- NCT06576492
- Testing
- RV4986A lotion
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Keloid
Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars
This trial will assess the safety and efficacy of 50 and 200ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe.
- Trial name
- NCT00469235
- Testing
- Avotermin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Renovo